$REPL +43% Premarket 🚀 🔹 Replimune is ripping after reports it may get another shot at FDA approval for RP1 in advanced melanoma 📈 🔹 RP1 is an oncolytic imm

$REPL +43% Premarket 🚀 🔹 Replimune is ripping after reports it may get another shot at FDA approval for RP1 in advanced melanoma 📈 🔹 RP1 is an oncolytic immunotherapy being developed with Bristol Myers’ Opdivo 💉 🔹 Prior FDA setbacks crushed the stock, so any renewed regulatory path is a major …